Developer of biology-guided radiotherapy designed to create a new cancer treatment modality.
Developer of biology-guided radiotherapy designed to create a new cancer treatment modality.
Therapeutic Devices📍 Hayward, CAFounded 2009
Current Valuation
$1.3B
as of 2023-Q4
UNICORN
QL Price
$1.3B
0% vs last round
QuantLogix's current estimate for RefleXion Medical, published 2026-09-07 — in line with the last disclosed round of $1.3B (2023-Q4).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$1.3B
2023-Q4
weight 0.16
How this price has held up
No round has priced for RefleXion Medical since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-07 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, RefleXion Medical, 2026-09-07 (23d7e75e034d28c2).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is RefleXion Medical going public?
No. RefleXion Medical is private and has not filed to go public. There is no S-1 on file.
What is RefleXion Medical's valuation in 2026?
RefleXion Medical is valued at $1.3B as of 2023-Q4, set by its Series F ($106.71M, Nov 2023). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has RefleXion Medical filed an S-1?
No public S-1 is on file for RefleXion Medical.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2009
HQ
Hayward, CA
Employees
236
Total Raised
$675.98M
Last Round
Series F — $106.71M (Nov 2023)
IPO Status
private
Fundraising Status
Series F · $106.71M · 2y 10mo ago
privateTotal raised $675.98M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series F
$106.71M
Nov 2023
—
$1.3B
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
3
2 active · 1 recruiting
Focus areas
Cancer
Tumor, Solid · Cancer, Lung
Latest trial start
2025-12-01
Name-verified against lead sponsor "RefleXion Medical" on ClinicalTrials.gov as of 2026-09-03. Verify on ClinicalTrials.gov ↗
Talent Signal
No public careers page or job board could be found for RefleXion Medical as of 2026-08-17. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.
MedicalHealth CareTherapeuticsMedical Device
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2023-Q4. Refreshed quarterly.